Results 81 to 90 of about 1,815 (184)

Boscisucrophage: A Natural SGLT1/2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes

Food Science &Nutrition, Volume 14, Issue 3, March 2026.
Boscisucrophage (BSP) significantly reduced blood glucose and HbA1c, increased urine glucose excretion, and improved functional symptoms in T2DM patients resistant to oral antihyperglycemic drugs. BSP showed no adverse effects on liver or kidney function.
Bruno Eto, Amal Elrherabi, Fahd A. Nasr, Joe Miantezila Basilua, Ahlam Outman, Rosette Christelle Ndjip, Mohamed Bouhrim, Mohammed Al‐zharani, Ashraf Ahmed Qurtam, Brahim Ibet, Bernard Gressier, Jehan‐François Desjeux   +11 more
wiley   +1 more source

Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses

Endocrinology, Diabetes & Metabolism
Aims How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes has not been clinically demonstrated. Thus, we compared time courses of gamma‐glutamyltransferase (GGT) and alanine aminotransferase (ALT) with ...
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura, Hideki Suganami   +5 more
doaj   +1 more source

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

Molecules, 2020
Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the ...
Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Hideaki Yokoo, Aya Osaki, Yoko Shimoda, Atsushi Ozawa, Yasuyo Nakajima, Jeffrey E. Pessin, Shuichi Okada, Masanobu Yamada   +10 more
doaj   +1 more source

Incidence of Diabetic Ketoacidosis in Dapagliflozin‐Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 1, January 2026.
ABSTRACT Purpose Diabetic ketoacidosis (DKA) is an important identified risk of treatment with the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin, particularly in patients with type 1 diabetes mellitus (T1DM). We evaluated the DKA incidence rate (IR) among dapagliflozin‐treated Japanese patients with T1DM receiving concomitant insulin.
Reiko Tamura, Hyosung Kim, Yuko Takumi, Miyo Ishihara, Tomoko Kobayashi, Deborah Layton, Kei Sakamoto   +6 more
wiley   +1 more source

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)

FEBS Open Bio, 2019
The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested ...
Ryo Goto, Kenya Kamimura, Yoko Shinagawa‐Kobayashi, Norihiro Sakai, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Hiroshi Nishina, Shuji Terai   +14 more
doaj   +1 more source

Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study

Journal of Diabetes Investigation, 2020
Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood.
Mayu Tochiya, Hisashi Makino, Tamiko Tamanaha, Miki Matsuo, Ai Hishida, Ryo Koezuka, Yoko Ohata, Tsutomu Tomita, Choel Son, Yoshihiro Miyamoto, Satoshi Yasuda, Kiminori Hosoda   +11 more
doaj   +1 more source

Chronic inflammation is not associated with attenuated sodium‐glucose co‐transporter 2 inhibitor‐induced hemoglobin increase in patients with diabetes

Journal of Diabetes Investigation, Volume 17, Issue 1, Page 25-33, January 2026.
ABSTRACT Aims/Introduction This study aimed to investigate whether the use of sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) is associated with an increase in hemoglobin in the presence of chronic inflammation. Materials and Methods This is a matched‐pair cohort study.
Miho Murashima, Kodai Suzuki, Takahisa Kasugai, Yuki Miyaguchi, Maki Hiratsuka, Tatsuya Tomonari, Minamo Ono, Masashi Mizuno, Tomohiro Tanaka, Takayuki Hamano   +9 more
wiley   +1 more source

Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2019
Abstract Context Although calorie loss from increased urinary glucose excretion continues after long-term treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is), the mechanisms of the attenuated weight loss due to SGLT2is are not well known.
Akihiro Yoshida, Yasuhiro Matsubayashi, Toshiaki Nojima, Hideki Suganami, Takahiro Abe, Masahiro Ishizawa, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku, Hirohito Sone   +9 more
openaire   +2 more sources

Sodium–Glucose Cotransporter 2 Inhibitors in Diabetic Solid Organ Transplant Recipients: A Systematic Review and Meta‐Analysis of Comparative Studies

Journal of Diabetes Research, Volume 2026, Issue 1, 2026.
Background Solid organ transplant recipients with diabetes mellitus face unique challenges in glycemic control, compounded by the metabolic effects of immunosuppressants. Although sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective in diabetes, evidence for their use in transplant recipients remains limited.
Min Jung Geum, Kyung Sun Oh, Young-Mi Ah, Eusebio Chiefari   +3 more
wiley   +1 more source

Clinical characteristics and outcomes of diabetes‐related ketoacidosis (DKA) in sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) users with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 27, Issue 12, Page 6999-7009, December 2025.
Abstract Aim Sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) offer significant cardiorenal benefits for people with type 2 diabetes (PwT2D). However, concerns remain regarding their association with diabetes‐related ketoacidosis (DKA). (1) To compare demographics, precipitating factors, biochemical features, management, and outcomes of acute DKA ...
Angelica Sharma, Shams Ali Baig, Rasiah Thayakaran, Lakshmi Rengarajan, Nevil C. Philip, Anu Ann Abraham, Aspasia Manta, Parth Narendran, Ketan Dhatariya, Guillermo E. Umpierrez, Punith Kempegowda, DEVI collaboration   +11 more
wiley   +1 more source